Evidence map›Paper›PMID 33294443›Full record

ReviewBioMed research international2020

Mechanism by which TRAF6 Participates in the Immune Regulation of Autoimmune Diseases and Cancer.

Jingjing Wang, Xinjie Wu, Mengyu Jiang, Guixiang Tai

Open access · hybridAbstract readReview
In one paragraph

Review in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. miRNA-146b TargetsAnimals : an open access journal from MDPI · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Molecular Mechanism of TRAF6 in Malignant Proliferation of Human NK/T Cell Lymphoma Cell HANK1.Mediterranean journal of hematology and infectious diseases · 2025
    Article
  11. Article
  12. TheInternational journal of molecular sciences · 2024
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jingjing WangDepartment of Immunology, College of Basic Medical Science, Jilin University, Xinjiang Street 125, Changchun 130021, China.ORCID https://orcid.org/0000-0001-7385-3694
Xinjie WuDepartment of Immunology, College of Basic Medical Science, Jilin University, Xinjiang Street 125, Changchun 130021, China.ORCID https://orcid.org/0000-0003-1622-0043
Mengyu JiangDepartment of Immunology, College of Basic Medical Science, Jilin University, Xinjiang Street 125, Changchun 130021, China.ORCID https://orcid.org/0000-0001-8901-2734
Guixiang TaiDepartment of Immunology, College of Basic Medical Science, Jilin University, Xinjiang Street 125, Changchun 130021, China.ORCID https://orcid.org/0000-0003-3672-4361
Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6), an E3 ubiquitin ligase, is a signal transduction molecule shared by the interleukin-1 receptor (IL-1R)/Toll-like receptor (TLR) family and the TNFR superfamily. TRAF6 has a unique TRAF domain and RING finger domain that mediate intracellular signaling events. In the immune system, TRAF6-mediated signaling has been shown to be critical for the development, homeostasis, and activation of a variety of immune cells, including B cells, T cells, dendritic cells, and macrophages. Although the pathogenesis and etiology of autoimmune diseases and cancer are not fully understood, it is worth noting that existing studies have shown that TRAF6 is involved in the pathogenesis and development of a variety of these diseases. Herein, we reviewed the role of TRAF6 in certain immune cells, as well as the function and potential effect of TRAF6 in autoimmune diseases and cancer. Our review indicates that TRAF6 may be a novel target for autoimmune diseases and cancer.

Indexed as

Autoimmune DiseasesHumansLymphocytesNeoplasmsProteasome Endopeptidase ComplexTNF Receptor-Associated Factor 6UbiquitinationProteasome Endopeptidase ComplexTNF Receptor-Associated Factor 6

Identifiers

PMID33294443
PMCPMC7714562
OpenAlexW3106653192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.